Integrating Process Analytical Technology (PAT) for Real-Time Monitoring of AAV Bioreactor Cultures
PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES
Integrating Process Analytical Technology (PAT) for Real-Time Monitoring of AAV Bioreactor Cultures
Integrating Process Analytical Technology for AAV Bioreactor Cultures
CELL & GENE | RNA | BIOLOGICS
A Framework for Data-Driven AAV Bioprocess Control
Executive Summary
Process Analytical Technology (PAT) provides the real-time monitoring necessary to transition adeno-associated virus (AAV) manufacturing from a reactive, endpoint-driven model to a proactive, data-informed process. By integrating in-line sensors and analytical tools directly into bioreactor systems, we can continuously track influential process parameters and their effect on vector quality attributes like titer, purity, and full/empty capsid ratios. This approach builds a robust process design space, minimizes batch-to-batch variability, and accelerates the path to a successful IND submission, typically within an 18-24 month timeline. Franklin Biolabs leverages this methodology within its >100,000 sq ft facility to de-risk vector production for next-generation therapies.
Technical FAQ
What is Process Analytical Technology (PAT) in the context of AAV manufacturing?
PAT is a framework for designing, analyzing, and controlling manufacturing through timely measurements of quality and performance attributes of raw and in-process materials. For AAV production, this means using in-line sensors (e.g., Raman spectroscopy, capacitance probes) to monitor bioreactor conditions like cell density, viability, nutrient consumption, and metabolite concentration in real time.
How does PAT improve upon traditional AAV production methods?
Traditional methods rely on offline sampling and endpoint testing, introducing time lags and potential for process deviations to go unnoticed for hours or days. PAT provides continuous data streams, enabling immediate process adjustments to maintain optimal conditions, thereby improving consistency, yield, and final vector quality.
Which specific parameters can be monitored using PAT in an AAV bioreactor?
Commonly monitored parameters include viable cell density, pH, dissolved oxygen, glucose, lactate, and ammonia. Advanced applications can also provide insights into viral particle assembly and concentration, directly informing the harvest timing for maximal yield of functional vector.
Is this approach applicable to both suspension and adherent AAV platforms?
Yes. While implementation details differ, the principles of PAT are applicable to both Sartorius single-use suspension bioreactors and iCELLis fixed-bed adherent systems. The goal remains the same: to gain a deeper, real-time understanding of the cell culture environment to control vector production.
From Endpoint Analytics to Real-Time Process Control
Conventional AAV manufacturing workflows often depend on offline analytics to assess the state of a bioreactor culture. This retrospective approach can fail to capture transient events that impact vector yield and quality, leading to process variability that complicates regulatory submissions. A manufacturing process that is not well understood or tightly controlled presents a significant risk to program timelines.
Implementing a PAT framework allows for a shift from reactive troubleshooting to proactive process steering. By collecting high-frequency data directly from the bioreactor, we can build predictive models that correlate in-process measurements with final vector attributes.
Core Technologies for In-Line AAV Monitoring
Several analytical technologies are suited for integration into GxP-compliant AAV production environments. The selection is tailored to the specific process, cell line, and AAV serotype.
-
Raman Spectroscopy: Provides non-invasive, real-time chemical analysis of the cell culture media, tracking concentrations of key nutrients, metabolites, and even protein products.
-
Capacitance Probes: Measure the dielectric properties of the cell suspension, offering a reliable indicator of viable cell density without the need for physical sampling.
-
Near-Infrared Spectroscopy (NIRS): Can be used to monitor multiple analytes simultaneously, offering a comprehensive view of the culture’s metabolic state.
We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. The Franklin Biolabs team is integral to our AAV-vector based gene therapy candidate development, and we hope to continue the collaboration for years to come.
— Biotech Partner
Building a Data-Driven Process Design Space
The value of PAT is its ability to define a robust process design space. The insights gained from foundational research, such as the need for long-term, regulated transgene expression (PMID: 15507527) or the identification of specific proteins governing vector biodistribution (PMID: 30819613), directly inform which quality attributes must be rigorously controlled. A well-defined process links these biological requirements to specific, measurable parameters in the bioreactor.
This data-rich approach establishes a clear understanding of how process inputs affect vector quality, ensuring consistency from 2L development runs to 500L+ production scales. These efforts result in Strategic Process Blueprints Accelerating Technology Transfer, whether to an internal GMP suite or an external organization. This methodology has been a component of the 100% successful IND rate achieved by our scientific leadership since 2019, prior to the formal launch of the Franklin Biolabs brand in 2024.
This detailed process knowledge is fundamental for preparing the Chemistry, Manufacturing, and Controls (CMC) section of an Investigational New Drug (IND) or Investigational Medicinal Product Dossier (IMPD) submission.
Return to the main Large-Scale AAV Manufacturing and Process Development hub.
Technical Visualization: PAT-Integrated AAV Biomanufacturing Workflow
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.